Turning Point Therapeutics, Inc.
TPTXDelisted Aug 17, 2022- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001595893
Turning Point Therapeutics, Inc. was delisted on Aug 17, 2022; its insiders filed their last Form 4 on Aug 17, 2022; 209 institutions reported holding it in 13F filings for Q2 2022, worth $3.29B in total; Soros Fund Management was the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Turning Point Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Turning Point Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Machado Patrick | Director | – | Aug 17, 2022 | 0 |
| Gallagher Carol Giltner | Director | – | Aug 17, 2022 | 0 |
| Alles Mark J | Director | 0 | Aug 17, 2022 | 0 |
| Countouriotis Athena | President & CEO | 0 | Aug 17, 2022 | 0 |
| George Simeon | Director | 0Indirect | Aug 17, 2022 | 0 |
| Nicholson Garry A | Director | – | Aug 17, 2022 | 0 |
| Hirmand Mohammad | EVP and Chief Medical Officer | 0 | Aug 17, 2022 | 0 |
| Tombesi Paolo | EVP & Chief Financial Officer | 0 | Aug 17, 2022 | 0 |
| Bodem Barbara W. | Director | – | Aug 17, 2022 | 0 |
| Sun Brian | SVP & General Counsel | 0 | Aug 17, 2022 | 0 |
| Sabus Steve M | SVP & Chief Commercial Officer | 0 | Aug 17, 2022 | 0 |
| North Annette | EVP & General Counsel | 27,979 | Feb 11, 2022 | 0 |
| Reich Siegfried | EVP & Chief Scientific Officer | 17,015 | Feb 11, 2022 | 0 |
| Partridge Andrew John | EVP & Chief Commercial Officer | 38,361 | Feb 11, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 29, 2022 (view filing) | Jul 27 | 2 days | Tombesi PaoloEVP & Chief Financial Officer | SSale | −1.18K | $74.94 | −$88.7K | −4.0%28.7K after | |
| Feb 11, 2022 (view filing) | Feb 9 | 2 days | Reich SiegfriedEVP & Chief Scientific Officer | SSale | −397 | $36.30 | −$14.4K | −10.3%3.45K after | |
| Feb 11, 2022 (view filing) | Feb 9 | 2 days | Partridge Andrew JohnEVP & Chief Commercial Officer | SSale | −221 | $36.30 | −$8.02K | −1.0%22.1K after | |
| Feb 11, 2022 (view filing) | Feb 9 | 2 days | North AnnetteEVP & General Counsel | SSale | −669 | $36.30 | −$24.3K | −5.4%11.7K after | |
| Feb 11, 2022 (view filing) | Feb 9 | 2 days | Hirmand MohammadEVP & Chief Medical Officer | SSale | −669 | $36.30 | −$24.3K | −8.9%6.84K after | |
| Feb 11, 2022 (view filing) | Feb 9 | 2 days | Countouriotis AthenaPresident & CEO | SSale | −2.97K | $36.30 | −$107.8K | −5.8%47.9K after | |
| Aug 31, 2021 (view filing) | Aug 30 | 1 day | North AnnetteEVP, General Counsel & Secty. | SSale | −10.0K | $80.00 | −$800.0K | −44.7%12.4K after | |
| Jul 15, 2021 (view filing) | Jul 14 | 1 day | Partridge Andrew JohnEVP & Chief Commercial Officer | SSale | −1.87K | $74.90 | −$140.0K | −7.9%21.8K after |